

24 June 2016

ASX Code: MXC

Resignation of Director – Mr Nick Castleden

MGC Pharmaceuticals Ltd (ASX: MXC, or “the Company”) would like to advise the market of the resignation of Board member Mr Nick Castleden as Non-Executive Director effective 24 June 2016. Mr Castleden, who joined the Board in May 2014, has offered his resignation to focus on other business interests.

The Board wishes to express its appreciation to Mr Castleden for his dedication to the role over the last two years and wish him all the best in his future endeavours. An Appendix 3Z is attached for Mr Castleden.

The Board of MGC Pharmaceuticals Ltd now consists of:

Mr Brett Mitchell – Executive Chairman
Mr Nativ Segev – Managing Director
Mr Roby Zomer – Executive Director
Dr Ross Walker – Non-Executive Director

-Ends-

For further information, please contact:

Media Enquiries

Andrew Ramadge
Senior Account Manager
Media and Capital Partners
+61 475 797 471
andrew.ramadge@mcpartners.com.au

MGC Pharmaceuticals Ltd

Brett Mitchell
Executive Chairman
+61 8 9389 2000
info@mgcpharma.com.au

About MXC

MGC Pharmaceuticals Ltd (ASX: MXC) is EU based specialist medical cannabis company with many years of technical and commercial experience in the medical cannabis industry. The Company’s founders were key figures in the Israeli medical cannabis industry and the core business strategy is to develop and supply high quality non-psychoactive Cannabidiol (CBD) resin extract to the growing demand in cosmetics and medical markets in Europe, North America and Australasia. The Company is also developing strategic joint ventures in these key value add industries, as demonstrated with MGC Derma CBD cosmetics.

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	MGC PHARMACEUTICALS LTD
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	David Nicholas Castleden
Date of last notice	27 May 2016
Date that director ceased to be director	24 June 2016

Part 1 – Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities David Nicholas Castleden 2,000,000 Ordinary Shares 3,500,000 Unlisted Options exercisable at \$0.04 each on or before 30 June 2017

+ See chapter 19 for defined terms.

Appendix 3Z
Final Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest	Number & class of securities
Anna Louise Murphy (wife)	1,185,148 Ordinary Shares

Part 3 – Director's interests in contracts

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

+ See chapter 19 for defined terms.